- Home
- IP vs GH Comparison
IP vs GH Comparison
Compare IP & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IP | GH |
|---|---|---|
| Founded | 1898 | 2011 |
| Country | United States | United States |
| Employees | 62602 | N/A |
| Industry | Paper | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 20.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | IP | GH |
|---|---|---|
| Price | $37.91 | $150.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $45.67 | ★ $119.79 |
| AVG Volume (30 Days) | ★ 5.0M | 2.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.51% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $7.98 | $33.30 |
| Revenue Next Year | $3.53 | $28.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $29.26 | $40.36 |
| 52 Week High | $56.13 | $174.08 |
Technical Indicators
Market Signals| Indicator | IP | GH |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 51.87 |
| Support Level | $35.74 | $94.02 |
| Resistance Level | $37.53 | $174.08 |
| Average True Range (ATR) | 1.22 | 7.30 |
| MACD | -0.17 | -2.74 |
| Stochastic Oscillator | 52.96 | 20.29 |
Price Performance
Historical ComparisonAbout IP International Paper Company
International Paper manufactures packaging products. It accounts for roughly one-third of the North American corrugated packaging market. The company also has a substantial presence in Europe following its acquisition of DS Smith. International Paper serves a variety of end markets, including industrial, consumer products, and manufacturing.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.